Citrine Medicine, a Shanghai rare disease company, in-licensed China rights to a pediatric therapy for congenital adrenal hyperplasia (CAH) developed by the UK 's Diurnal Group. Alkindi ® is an adrenal hormone replacement therapy, the first approved treatment for the rare genetic condition. It is a patented, oral, immediate-release hydrocortisone formulated in encapsulated granules that can be opened for age-appropriate dosing. Children with adrenal insufficiency, including the genetic condition CAH, suffer from cortisol deficiency, causing chronic fatigue and potential death. More details.... Stock Symbol: (AIM: DNL) Share this with colleagues: // //